Bezuclastinib

Cogent Biosciences is pushing bezuclastinib toward FDA approval for nonadvanced systemic mastocytosis (NonAdvSM), with a December 30, 2026 PDUFA date on the NDA supported by the SUMMIT Phase 2 registrational trial (NCT05186753) [1]. Topline SUMMIT data reported in mid-2025 showed a mean 24.3-point reduction in total symptom score at 24 weeks on bezuclastinib versus 15.4 points on placebo, an 8.91-point placebo-adjusted improvement (p=0.0002), plus 87.4% of bezuclastinib patients achieving at least a 50% serum tryptase reduction versus 0% on placebo [10]. The drug selectively blocks KIT D816V, the gain-of-function mutation driving mast cell overgrowth in roughly 95% of systemic mastocytosis patients [8]. Its main differentiation from Blueprint Medicines' already-approved avapritinib is minimal brain penetration in preclinical distribution studies [13], which should translate to fewer cognitive side effects than avapritinib's roughly 34% cognitive-AE incidence in PATHFINDER (8% grade 3 or higher) [6]. The NDA is under FDA review with Orphan Drug and Fast Track designations [11]. Beyond SUMMIT, Cogent runs the Phase 3 PEAK trial combining bezuclastinib with sunitinib in imatinib-resistant GIST [3], positioning the asset as a two-indication opportunity rather than a single-shot rare disease play. For a single-asset small-cap, the December PDUFA is the entire company.

Bezuclastinib is a novel small molecule, never approved anywhere. Cogent Biosciences (Nasdaq: COGT) develops the compound, formerly known as CGT9486. FDA accepted the NDA for nonadvanced systemic mastocytosis in March 2026, assigning a PDUFA action date of December 30, 2026 [11]. Cogent has disclosed Orphan Drug and Fast Track designations for the NonAdvSM program [11]. Selected dose in SUMMIT Part 2 was 100 mg once daily using the optimized formulation, after Part 1 evaluated 50, 100, or 200 mg twice daily and 400 mg once daily during dose optimization [10, 13]. The clinical program is broader than a single indication. SUMMIT (NCT05186753) [1] is the Phase 2 registrational monotherapy study in indolent and smoldering SM that anchors the NDA. APEX (NCT04996875) [2] is the Phase 2 monotherapy study in advanced SM, with data supporting a potential second SM label expansion. Separately, PEAK (NCT05208047) [3] is a Phase 3 trial of bezuclastinib plus sunitinib versus sunitinib alone in GIST patients who progressed on imatinib; primary readout is expected in 2027. SARC044 (NCT06208748) [4] is an investigator-sponsored Phase 2 also in GIST. Because the NDA is filed and under active FDA review, this asset is at the regulatory review stage rather than an unread Phase 2. The near-term catalyst is the PDUFA action, not a trial readout. APEX interim data in advanced SM are expected in the second half of 2026, which could open a potential second SM label.

Mast cells are immune cells that sit under the skin, in the gut lining, and in bone marrow, releasing histamine and other inflammatory chemicals when triggered by allergens. In systemic mastocytosis, a single-letter mutation in the KIT gene (KIT is a receptor on the mast cell surface that normally receives growth signals) called D816V flips the receptor into an always-on state, driving uncontrolled mast cell proliferation and constant symptom flares like flushing, itching, GI cramping, brain fog, and anaphylaxis [8]. Bezuclastinib binds and inhibits the mutant KIT selectively, quieting the abnormal signal. Genetic evidence for the target is airtight. D816V is present in roughly 95% of systemic mastocytosis patients and is directly causal, one of the cleanest oncogene-disease relationships in medicine [8]. Pharmacological validation is equally strong: Blueprint Medicines' avapritinib (FDA-approved in 2021 for advanced SM, expanded to indolent SM in 2023 [9]) proved KIT D816V blockade works clinically. In the PIONEER Phase 2 trial that supported the indolent SM label expansion, avapritinib 25 mg daily produced a 15.6-point TSS reduction at 24 weeks versus 9.2 points on placebo [14]. Bezuclastinib's differentiator is not the target but the pharmacokinetics. Avapritinib crosses the blood-brain barrier and has been linked to cognitive adverse events (memory lapses, mental slowing) at therapeutic doses. In PATHFINDER (advanced SM), cognitive effects occurred in roughly 34% of avapritinib-treated patients, with grade 3 or higher events in about 8% [6]. Bezuclastinib was designed to stay out of the CNS: preclinical tissue distribution studies showed minimal brain penetration, and no CNS toxicities were identified preclinically [13]. Published bezuclastinib CNS-to-plasma ratios in humans have not been disclosed. If the safety data hold, minimal CNS exposure is a real clinical advantage in a chronic-dosing indication where patients take the drug for years.

SUMMIT (NCT05186753) [1] is a multi-part, randomized, double-blind, placebo-controlled Phase 2 registrational trial in adults with indolent or smoldering systemic mastocytosis. Part 1 identified the recommended Phase 2 dose (100 mg once daily, optimized formulation). Part 2 enrolled the pivotal cohort, with a target enrollment of 237 patients randomized to bezuclastinib or placebo on top of background best supportive care [1]. Primary endpoint is change in total symptom score using the validated ISM-SAF (Indolent Systemic Mastocytosis Symptom Assessment Form) at 24 weeks. Key secondary endpoints include change in serum tryptase (a mast cell burden marker), change in KIT D816V allele burden in peripheral blood, and change in mast cell infiltrates on bone marrow biopsy. The design is defensible. Nonadvanced SM patients live for decades with intermittent severe symptoms, so a survival endpoint is not tractable. The FDA accepted the same symptom-score-plus-biomarker construct for avapritinib's PIONEER trial that supported the indolent SM label expansion in 2023 [9, 14], so regulatory precedent is clean. Cogent reported topline SUMMIT data with statistically significant improvement over placebo across primary and key secondary endpoints [10]. Specifically: bezuclastinib produced a 24.3-point mean TSS reduction versus 15.4 points on placebo (placebo-adjusted 8.91 points, p=0.0002), and 87.4% of bezuclastinib patients achieved at least a 50% reduction in serum tryptase versus 0% on placebo [10]. Full data were presented at the American Society of Hematology (ASH) 2025 annual meeting and again at AAAI 2026 [15]. Safety profile has been described as consistent with prior bezuclastinib studies, with no new cognitive signals disclosed in the topline release [10]. The trial is currently active but not recruiting, since the pivotal cohort has read out [1]. Enrollment execution was reasonable given the rare disease patient pool.

This drug is under FDA review (NDA/BLA), with a PDUFA decision date of 2026-12-30. Our estimate of 93% is the historical filing-approval rate for its area, adjusted for its rejection history (no prior Complete Response Letters). At this stage the early-trial design model no longer applies - what matters is that it reached the FDA and whether it has been rejected before.

Efficacy risk is relatively contained. SUMMIT hit its primary and key secondary endpoints with large effect sizes (placebo-adjusted 8.91-point TSS improvement, p=0.0002; 87.4% versus 0% on 50%-tryptase-reduction) [10], and the mechanism is genetically causal, so the probability that FDA rejects on efficacy grounds is low. The remaining efficacy question is durability: nonadvanced SM is a chronic condition, and long-term data will matter for both label language and payer negotiations. Bezuclastinib's Phase 2 patient-years are still limited. Safety risk is the most active concern. Avapritinib's cognitive AE profile is documented across EXPLORER [5], PATHFINDER (cognitive effects in ~34% of patients, grade 3+ in ~8%) [6], and the approved label. Bezuclastinib was designed for minimal CNS penetration, and preclinical data support that [13], but the label will disclose the full safety picture from over a year of patient dosing. Off-target liver enzyme elevations have appeared across the multikinase inhibitor class historically [7]. A boxed warning on any cardiac, hepatic, or neurologic axis would compress the commercial delta versus avapritinib. Execution risk centers on the PDUFA and Cogent's balance sheet. Cogent is effectively a single-asset commercial-stage story. The company has publicly communicated cash runway into 2027 [12], but a Complete Response Letter (CRL, the FDA's mechanism for declining to approve without formal rejection) or a six-month PDUFA extension would likely force dilutive financing at a much lower valuation. Commercial risk is real. Blueprint's avapritinib has a two-plus-year head start in NonAdvSM, active payer contracts, and physician relationships built through key opinion leaders (KOLs, the high-volume physicians whose prescribing drives market uptake) [16]. Bezuclastinib needs a compelling cognitive-safety differentiation to win formulary switches. Avapritinib's list price in advanced SM has been reported in the $400,000-per-year range in trade press but Blueprint has not publicly confirmed a specific NonAdvSM WAC in a filing citation retrievable here; treat pricing anchor as directional, not verified [16]. Cogent has not disclosed bezuclastinib pricing.

Worth watching, closely. The December 30, 2026 PDUFA is the single most consequential catalyst on Cogent Biosciences' calendar and one of the cleanest binary events in small-cap biotech for the fourth quarter [11]. Positive readout is already partly priced given SUMMIT topline, so the setup skews toward incremental upside on approval plus modest label breadth, and sharp downside on any CRL, six-month extension, or restrictive label carve-out. Market sizing. US systemic mastocytosis prevalence is commonly estimated in the 30,000 to 50,000 patient range, with roughly 80 to 90% classified as indolent or smoldering (nonadvanced), implying a US NonAdvSM addressable population on the order of 25,000 to 45,000 patients. Actual diagnosed and treatment-eligible fractions are much smaller: many patients are undiagnosed or symptom-managed with antihistamines. Assuming avapritinib-comparable list pricing and 15 to 30% share of a diagnosed treatment population of 10,000 to 20,000 patients, a rough US peak revenue range for bezuclastinib in NonAdvSM is on the order of $500 million to $1.5 billion, depending on cognitive-safety differentiation and payer acceptance. Adding a positive PEAK GIST readout in 2027 would layer another indication on top. Specific signals to track: any Cogent SEC 8-K filing (the mandatory disclosure for material corporate events) reporting FDA information requests or unexpected advisory committee scheduling [11], Blueprint's avapritinib NonAdvSM sales trajectory in coming quarters (any deceleration attributable to cognitive AEs would strengthen bezuclastinib's differentiation pitch) [16], and APEX interim data in advanced SM expected in the second half of 2026 [2], which would open a second SM label. The PEAK Phase 3 in GIST is the second act [3]. A positive readout in 2027 turns Cogent from a single-indication rare disease company into a two-indication oncology story, materially changing the equity narrative and takeout math for larger acquirers. For readers watching KIT inhibitor space, Cogent's PDUFA is the near-term signal; PEAK is the medium-term option.